Auriga
Auriga USA is a research and trading platform that focuses on growth sectors within the Health Care and Technology verticals. We operate out of our main office in New York City, and also have satellite offices in Boston, San Francisco, Philadelphia, San Diego, and Washington D.C. This regional network helps us to keep abreast of key corporate developments, enhance client relationships, and provide more efficient product distribution to meet clients' investment needs. The firm is committed to providing our clients with critical information flow, investment ideas, and access to industry experts.
View Older Stories View More Recent Stories
-
Herbalife (HLF) Shares Continue Lower Despite Numerous 'Buy the Weakness' Calls
-
Auriga Maintains a 'Hold' on Fresh Del Monte (FDP); Quarter Review
-
Auriga Reiterates a 'Buy' on Myriad Genetics (MYGN); Raising PT on Strong Results
-
Auriga maintains a 'Hold' on Thoratec (THOR); Q1 Review
-
Auriga Reiterates a 'Buy/Top Pick' on Medidata Solutions (MDSO); "Apple" of Clinical Trial Software
-
UPDATE - Auriga Upgraded Dynamic Materials (BOOM) to Buy; Recent Dip Offers Buying Opportunity
-
UPDATE - Auriga Upgraded Herbalife (HLF) to Buy; Accumulate Shares on Dip
-
Notable Analyst Rating Changes 05/02: (GNW) (ACI) (HLF) Upgraded; (RSH) (COP) (EQT) Downgraded
-
Auriga Upgrades Dynamic Materials (BOOM) to Buy
-
Auriga Upgrades Herbalife (HLF) to Buy
-
Auriga Downgrades Collective Brands (PSS) to Hold
-
Auriga Maintains a 'Hold' on Herbalife (HLF); Beating Sustained Growth
-
Auriga Downgrades McKesson (MCK) to Hold; Drilling Down...Strong Q4 From Stock Buybacks
-
Auriga Downgrades LDK Solar (LDK) to Sell; Slope of Hope is Steep
-
Auriga Starts Broadsoft (BSFT) at Buy; IP Flexibility Both Provocative and Advantageous
-
Traders Eye Protalix BioTherapeutics (PLX) Ahead of FDA PDUFA Date
-
Auriga Maintains a 'Hold' on Herbalife (HLF); Expect Improvement in 1Q
-
Auriga Maintains a 'Buy' on Boston Beer Company (SAM); Q1 Preview
-
Auriga Maintains a 'Buy' on Dole (DOLE); Q1 Preview - Expect Beat, But Tough Comparisons
-
Auriga Reiterates a 'Buy' on Apple (AAPL); China, an Untapped Opportunity
-
Auriga reiterates a 'Buy' on Astronics (ATRO); Q1 Preview: Expect Beat
-
Auriga Reiterates a 'Buy' on Computer Programs and Systems (CPSI); Mixed Quarter and Outlook Strong
-
Auriga Reiterates a 'Sell' on athenahealth (ATHN); Q1 Demonstrates Progress
-
UPDATE - Auriga Downgraded Protalix BioTherapeutics (PLX) to Hold; Odds of FDA Approval Are Difficult to Gauge
-
Auriga Downgrades Protalix BioTherapeutics (PLX) to Hold
-
Auriga Reiterates a 'Buy' on Carpenter Technology (CRS); Raising PT & Estimates
-
Auriga Reiterates a 'Buy' on GrafTech International (GTI); Tweaking 2012 Estimates
-
Auriga Maintains a 'Hold' on Columbia Sportswear (COLM); Cutting FY Estimates on Weakening Trends
-
UPDATE - Auriga Downgraded Deckers Outdoor (DECK) to Hold; Moving To Sidelines As Risk Increases
-
Notable Analyst Rating Changes 04/27: (SNDK) (ZNGA) (AMZN) Upgraded; (MDRX) (STX) (DECK) Downgraded
-
Auriga Downgrades Deckers Outdoor (DECK) to Hold
-
Notable Analyst Rating Changes 04/26: (ROK) (DPS) (APD) Upgraded; (HES) (ABB) (LEAP) Downgraded
-
Auriga Maintains a 'Hold' on Weight Watchers (WTW); Q1 Preview
-
Auriga Maintains a 'Hold' on Nutrisystem (NTRI); Q1 Earnings Preview: Expecting Lackuster Results
-
Auriga Maintains a 'Hold' on Skechers USA (SKX); Raising PT on Q1 Upside, But New Products Still in Test Mode
-
Auriga Reiterates a 'Buy' on Ubiquiti Networks (UBNT); Raising PT on Strong March Sales of UniFi
-
Auriga Reiterates a 'Buy' on Allegheny Technologies (ATI); Modestly Exceeding Expectations
-
Auriga Reiterates a 'Buy' on The Medicines Company (MDCO); Continues to make progress on all front
-
Auriga Maintains a 'Buy' on Thermo Fisher Scientific (TMO); Instruments and Consumables Performed Well
-
Auriga Maintains a 'Buy' on Impax Laboratories (IPXL); Generic Adderall XR Sales In-Line
-
UPDATE - Auriga Initiates Coverage on Forest Laboratories (FRX); Lack of Near Term Catalysts Keep Us Sidelined
-
Auriga Starts Medicis (MRX) at Buy; Favorable Risk/Reward Profile
-
Auriga Starts Forest Laboratories (FRX) at Hold
-
Auriga Starts Merck (MRK) at Buy
-
Auriga Reiterates a 'Buy' on Waters Corp. (WAT); Unexpectedly High Decline at Big Pharma Drags Down Results
-
Auriga Maintains a 'Buy' on Life Technologies (LIFE); Q1 Neatly Beats
-
Auriga Maintains a 'Buy' on Crane (CR); Strong Revs Offset by Margin Headwinds
-
Auriga Reiterates a 'Buy' on Apple (AAPL); International Attraction of the iPhone
-
Auriga Maintains a 'Buy' on CareFusion (CFN); Selling Neurodiagnostic Division Creates Less ConFusion
-
Streetinsider.com's Hot Lunchtime Reads 04/24: (NFLX) (WPI) (ILMN) (FIO) (CXW)

